Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04702113Not ApplicableCompleted

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

Role: lead

NCT04597593Completed

Association Between Genetic Variant Scores and DOACs (DARES2)

Role: lead

NCT03894878Completed

Association Between Genetic Variant Scores and Warfarin Effect

Role: lead

NCT04580589Completed

DOAC ADRs Retrospective Study on Genetic Variations

Role: lead

NCT04770922Completed

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

Role: lead

NCT04580602Completed

Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects

Role: lead

NCT04247919Terminated

DOAC ADRs Retrospective Study

Role: lead

All 7 trials loaded